NBIX · Neurocrine Biosciences Inc · Share Buybacks
$156.22
-0.35 (-0.22%)
At close · Sep 11
Market Cap
$15.88B
Shares
101.65M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$500,000,000
as of 2025-02-28
Remaining Authorization
$266,300,000
as of 2026-06-30
Program Utilization
46.7%
$233,700,000 used of $500,000,000
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source | ||
|---|---|---|---|---|
| 2026-06-30 YTD | $66,000,000 | 10-Q, filed 2026-07-31 | ||
| 2025-12-31 | $167,700,000 | 10-K, filed 2026-02-11 | ||
| 2024-12-31 | $300,000,000 | 10-K, filed 2026-02-11 | ||
Key facts
CIK
914475
CUSIP
64125C109
13F (30d)
159 filings
157 filers
Visit website
Investor relations